Physician profile
Michael T Boler
NPI 1821071267
$9,166.15
in general payments reported to CMS, 2019-2025
39 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,402 · 2020: $1,695 · 2021: $2,102 · 2022: $1,593 · 2023: $215 · 2024: $59.59 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,957.16 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $1,337.64 | 2019-2022 | |
| Novo Nordisk INC | $900.82 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| W. L. Gore & Associates, INC. | $699.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $483.07 | 2019-2022 | |
| Pfizer INC. | $469.02 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $375.77 | 2019-2022 | |
| Glaxosmithkline, LLC. | $284.30 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $283.83 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $273.85 | 2019-2022 | |
| Lilly USA, LLC | $271.17 | 2020-2023 | Mounjaro |
| Sk Life Science, INC. | $215.83 | 2020-2022 | |
| Amgen INC. | $191.31 | 2019-2023 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.80 | 2019-2022 | |
| Abiomed | $179.43 | 2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.